LeadStory

CNBC

Wegovy receives FDA approval to treat serious liver disease

CNBC · Just In
CNBC
CNBC
Just In

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on Novo Nordisk, what new FDA approval on its Wegovy drug means for sales, and much more.

Breakdown
  • FDA approves Wegovy for treatment of MASH, a serious liver disease. 21s
  • MASH affects about 5% of people in the U.S. and one in three overweight or obese individuals globally. 29s
  • Analysts project the new indication could add nearly $2 billion in peak sales for Novo Nordisk. 49s
  • Wegovy and Ozempic will both be available for $4.99 a month for out-of-pocket payers. 1m 14s
  • Both drugs have the same active ingredient but are marketed for different conditions. 1m 31s
Health